Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Pimavanserin

Erica Cusick  1 , Vikas Gupta  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Pimavanserin

Erica Cusick et al.
Free Books & Documents

Excerpt

Pimavanserin is a medication used to treat and manage the hallucinations and delusions associated with Parkinson disease psychosis. It is in the atypical antipsychotic class of drugs. This activity reviews the indication, action, and contraindications for pimavanserin as a valuable agent in managing Parkinson disease psychosis. This activity will highlight the mechanism of action, adverse event profile, dosing, monitoring, relevant interactions, and other key factors pertinent for healthcare team members in the care of patients with Parkinson disease psychosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Erica Cusick declares no relevant financial relationships with ineligible companies.

Disclosure: Vikas Gupta declares no relevant financial relationships with ineligible companies.

References

    1. Hawkins T, Berman BD. Pimavanserin: A novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract. 2017 Apr;7(2):157-162. - PMC - PubMed
    1. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 08;383(9916):533-40. - PubMed
    1. Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, Factor SA, Friedman JH, Lang AE, Larsen NJ, Andersson C, Fredericks D, Weintraub D. Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov Disord. 2018 Nov;33(11):1769-1776. - PMC - PubMed
    1. Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, Norton J, Stankovic S. Pimavanserin: Potential Treatment For Dementia-Related Psychosis. J Prev Alzheimers Dis. 2018;5(4):253-258. - PMC - PubMed
    1. Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, Youakim JM, Owen R, Stankovic S, ADP Investigators Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018 Mar;17(3):213-222. - PubMed

Publication types

LinkOut - more resources